High expression of the inhibitory receptor BTLA in T-follicular helper cells and in B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia.

B- and T-lymphocyte attenuator (BTLA) is a lymphoid receptor that inhibits lymphocyte activation on interaction with its ligand, herpesvirus entry mediator (HVEM). We developed monoclonal antibodies against BTLA and HVEM to study their expression using immunohistochemical and flow cytometric analyses in human tissues. In reactive lymph nodes, they were both expressed in interfollicular T cells and in B cells from mantle and marginal zones. Within germinal centers, B cells were negative, whereas T follicular helper (TFH) cells were BTLA+ and follicular dendritic cells were HVEM+. BTLA was strongly expressed in chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/SLL, 19 of 19 positive) when compared with other small B-cell lymphomas, including follicular lymphoma (0 of 24 positive), mantle cell lymphoma (0 of 10 positive), and marginal zone lymphoma (0 of 5 positive). Our results suggest that down-regulation of the BTLA-HVEM pathway may be involved in germinal center B-cell activation. The specific high expression of BTLA in B-CLL/SLL represents a new potential diagnostic tool. The BTLA positivity of TFH cells may be a basis for designing future immunotherapies.

[1]  K. Stamatopoulos,et al.  Microenvironmental influences in chronic lymphocytic leukaemia: the role of antigen stimulation , 2008, Journal of internal medicine.

[2]  L. Xerri,et al.  Programmed death 1 is a marker of angioimmunoblastic T-cell lymphoma and B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia. , 2008, Human pathology.

[3]  Kenneth M. Murphy,et al.  A crucial role for HVEM and BTLA in preventing intestinal inflammation , 2008, The Journal of experimental medicine.

[4]  K. Murphy,et al.  Regulatory T Cell Expression of Herpesvirus Entry Mediator Suppresses the Function of B and T Lymphocyte Attenuator-Positive Effector T Cells1 , 2008, The Journal of Immunology.

[5]  C. Mackay,et al.  T follicular helper (TFH) cells in normal and dysregulated immune responses. , 2008, Annual review of immunology.

[6]  G. Freeman,et al.  CD160 inhibits activation of human CD4+ T cells through interaction with herpesvirus entry mediator , 2008, Nature Immunology.

[7]  J. Cyster,et al.  Role of CXCR5 and CCR7 in Follicular Th Cell Positioning and Appearance of a Programmed Cell Death Gene-1High Germinal Center-Associated Subpopulation1 , 2007, The Journal of Immunology.

[8]  M. Shlomchik,et al.  In vivo imaging studies shed light on germinal-centre development , 2007, Nature Reviews Immunology.

[9]  Q. Wang,et al.  Distinct expression and inhibitory function of B and T lymphocyte attenuator on human T cells. , 2007, Tissue antigens.

[10]  Jason G. Cyster,et al.  Imaging of Germinal Center Selection Events During Affinity Maturation , 2007, Science.

[11]  M. Mahajan,et al.  A limited number of genes are involved in the differentiation of germinal center B cells , 2006, Journal of cellular biochemistry.

[12]  C. Nelson,et al.  Balancing co-stimulation and inhibition with BTLA and HVEM , 2006, Nature Reviews Immunology.

[13]  G. Freeman,et al.  Programmed Death-1 (PD-1) is a Marker of Germinal Center-associated T Cells and Angioimmunoblastic T-Cell Lymphoma , 2006, The American journal of surgical pathology.

[14]  H. Rahn,et al.  Follicular B helper T cell activity is confined to CXCR5hiICOShi CD4 T cells and is independent of CD57 expression , 2006, European journal of immunology.

[15]  M. Azuma,et al.  Expression and function of the B and T lymphocyte attenuator (BTLA/CD272) on human T cells. , 2006, Biochemical and biophysical research communications.

[16]  K. Murphy,et al.  Cutting Edge: B and T Lymphocyte Attenuator and Programmed Death Receptor-1 Inhibitory Receptors Are Required for Termination of Acute Allergic Airway Inflammation1 , 2006, The Journal of Immunology.

[17]  yang-xin fu,et al.  NK-cell activation by LIGHT triggers tumor-specific CD8+ T-cell immunity to reject established tumors. , 2006, Blood.

[18]  N. Chiorazzi,et al.  B‐Cell Chronic Lymphocytic Leukemia, a Clonal Disease of B Lymphocytes with Receptors that Vary in Specificity for (Auto)antigens , 2005, Annals of the New York Academy of Sciences.

[19]  J. Kaye,et al.  Functional Analysis of B and T Lymphocyte Attenuator Engagement on CD4+ and CD8+ T Cells1 , 2005, The Journal of Immunology.

[20]  K. Murphy,et al.  Differential Effects of B and T Lymphocyte Attenuator and Programmed Death-1 on Acceptance of Partially versus Fully MHC-Mismatched Cardiac Allografts1 , 2005, The Journal of Immunology.

[21]  K. Pfeffer,et al.  The role of herpesvirus entry mediator as a negative regulator of T cell-mediated responses. , 2005, The Journal of clinical investigation.

[22]  Wenjun Ouyang,et al.  A coreceptor interaction between the CD28 and TNF receptor family members B and T lymphocyte attenuator and herpesvirus entry mediator. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[23]  P. Lipsky,et al.  Regulation of B Cell Differentiation and Plasma Cell Generation by IL-21, a Novel Inducer of Blimp-1 and Bcl-61 , 2004, The Journal of Immunology.

[24]  T. Dörner,et al.  Involvement of inducible costimulator in the exaggerated memory B cell and plasma cell generation in systemic lupus erythematosus. , 2004, Arthritis and rheumatism.

[25]  C. Mackay,et al.  T Follicular Helper Cells Express a Distinctive Transcriptional Profile, Reflecting Their Role as Non-Th1/Th2 Effector Cells That Provide Help for B Cells1 , 2004, The Journal of Immunology.

[26]  J. Kaye,et al.  References Subscriptions Permissions Email Alerts An Inhibitory Ig Superfamily Protein Expressed by Lymphocytes and APCs Is Also an Early Marker of Thymocyte Positive Selection , 2013 .

[27]  K. Murphy,et al.  Characterization of phosphotyrosine binding motifs in the cytoplasmic domain of B and T lymphocyte attenuator required for association with protein tyrosine phosphatases SHP-1 and SHP-2. , 2003, Biochemical and biophysical research communications.

[28]  E. Jaffe.  Pathology and Genetics: Tumours of Haematopoietic and Lymphoid Tissues , 2003 .

[29]  J. Allison,et al.  BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1 , 2003, Nature Immunology.

[30]  Andreas Radbruch,et al.  Expression of ICOS In Vivo Defines CD4+ Effector T Cells with High Inflammatory Potential and a Strong Bias for Secretion of Interleukin 10 , 2003, The Journal of experimental medicine.

[31]  E. Devilard,et al.  In vivo expression of the CTLA4 inhibitory receptor in malignant and reactive cells from Human lymphomas , 1997, The Journal of pathology.

[32]  C. Ware,et al.  B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator , 2005, Nature Immunology.

[33]  G. Freeman,et al.  The B7 family revisited. , 2005, Annual review of immunology.

[34]  C. June,et al.  The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation. , 2005, Blood.

[35]  D. Olive,et al.  Anti‐interleukin 2 receptor monoclonal antibodies. Respective role of epitope mapping and monoclonal antibody‐receptor interactions in their antagonist effects on interleukin 2‐dependent T cell growth , 1986, European journal of immunology.